Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 137 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Promising Results Are Provided by Tebentafusp in Metastatic Uveal Melanoma December 12, 2020 11 Sun Safety Myths Debunked July 16, 2021 FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia November 3, 2021 FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with... November 20, 2025 Load more HOT NEWS FDA Approves Mirvetuximab Soravtansine-gynx for FRα-positive, Platinum-resistant Epithelial Ovarian, Fallopian Tube,... Utility of Prospective ctDNA Surveillance in Early TNBC and the Activity... New ESMO President 2029-2030 Elected How We’re Working to Help People With Cancer Across the World
